From DCAT Value Chain Insights (VCI)
MedImmune, the biologics arm of AstraZeneca, has appointed David Berman, MD, PhD, as head of the company’s Oncology Innovative Medicines unit (iMED) and senior vice president. In this role, he will lead the cross-functional teams responsible for the strategy, growth, and advancement of MedImmune’s biologics oncology portfolio.
Dr. Berman was most recently vice president and head of the Immuno-Oncology Exploratory Development Team for Bristol-Myers Squibb (BMS). Prior to joining BMS, David was an attending pathologist at the National Cancer Institute of the National Institute of Health and has written more than 40 published articles in scientific journals.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription